Participants must meet the following key inclusion criteria to be eligible for enrollment into the study:  Any participant who is receiving crizotinib and deriving clinical benefit (as determined by their doctor) in a Crizotinib Study which is planned to close. Participants must agree to follow the reproductive criteria as outlined in protocol. No ongoing Grade ≥3 or intolerable Grade 2 AEs considered to be related to crizotinib treatment, except for those laboratory eligibility criteria described in Inclusion #4. Adult Participants (≥18 years): Adequate hepatic and bone marrow function. Stable renal function for at least 14 days.  Pediatric Participants (<18 years): Adequate hepatic and bone marrow function. Stable renal function for at least 14 days.  Exclusion Criteria  Participants with any of the following characteristics/conditions will be excluded:  Female participants who are pregnant or breastfeeding. Any medical reason that, in the opinion of the investigator or sponsor, precludes the participant from inclusion in the study.